A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas
- Resource Type
- Short Communication
- Source
- In
Blood Advances 14 February 2023 7(3):314-316 - Subject
Lymphoid Neoplasia - Language
- ISSN
- 2473-9529